Category: Press Release - Psychedelic Alpha

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

Post published:August 16, 2022
Post category:Press Release

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

Post published:August 16, 2022
Post category:Press Release

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Post published:August 16, 2022
Post category:Press Release

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

Post published:August 15, 2022
Post category:Press Release

atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

Post published:August 15, 2022
Post category:Press Release

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing

Post published:August 13, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

Post published:August 12, 2022
Post category:Press Release

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

Post published:August 12, 2022
Post category:Press Release

MindMed Strengthens Board with Appointment of Two New Independent Directors

Post published:August 12, 2022
Post category:Press Release

MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

Post published:August 11, 2022
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

MindMed Strengthens Board with Appointment of Two New Independent Directors

MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.